FDA Orange Book · active-ingredient family
Polidocanol
Polidocanol is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:VARITHENA · NDA 205098
2
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VARITHENARLD×2 | BOSTON SCITFC | NDA 205098 | — | Dec 21, 2017 | |
| ASCLERARLD×2 | CHEMISCH FBRK KRSSLR | NDA 021201 | — | Mar 30, 2010 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7814943 | Nov 19, 2027 | in 1 yr 5 mo | ProductU-1461 |
| 9480652 | May 12, 2032 | in 6 yr | Product |
Polidocanol — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
